Yi Ming Pharmaceutical announced that the company plans to use 35 million yuan to 70 million yuan of its own capital to repurchase shares through centralized bidding for equity incentives or employee stock ownership plans. The repurchase price will not exceed 25.74 yuan/share. The repurchase period is within 12 months from the date the board of directors reviews and approves the repurchase plan. As of September 3, 2026, the company has repurchased a total of 204.1 million shares, accounting for 1.0704% of the total share capital. The highest transaction price is 18.00 yuan/share, the lowest transaction price is 16.96 yuan/share, and the total repurchase amount is 35.995 million yuan. It has reached the lower limit of total repurchase capital. The repurchase will continue to be carried out depending on the circumstances.

Yi Ming Pharmaceutical announced that the company plans to use 35 million yuan to 70 million yuan of its own capital to repurchase shares through centralized bidding for equity incentives or employee stock ownership plans. The repurchase price will not exceed 25.74 yuan/share. The repurchase period is within 12 months from the date the board of directors reviews and approves the repurchase plan. As of September 3, 2026, the company has repurchased a total of 204.1 million shares, accounting for 1.0704% of the total share capital. The highest transaction price is 18.00 yuan/share, the lowest transaction price is 16.96 yuan/share, and the total repurchase amount is 35.995 million yuan. It has reached the lower limit of total repurchase capital. The repurchase will continue to be carried out depending on the circumstances.